Kohler et al. Phase 1 study autologous CAR-Tregs in refractory RA. No lymphodepletion needed! 6 participants. 2 doses, second cohort with higher dose better and more sustained response. No CRS or other toxicities. @RheumNow #ACR25 Abstr#LB023 https://t.co/nWva2R7WOQ

#ACR25 Abstr#LB23 Phase 1 trial in 5 refractory #RA of SBT777101, a novel autologous CAR-Treg (without the need for lymphodepletion) showed promising efficacy and safety signal. No DLT, CRS or ICANS. Looking forward to larger data and in other RMDs @RheumNow https://t.co/YyGMSHjA3z

Turns out you can directly degrade NETs. Holy smokes NETs critical in pathology of SLE & other dx They’ve found you can target it Enzymatic degrader fused to albumin Proof-of-concept: degraded a patient’s SLE manifestations in hours Definitely one to watch #ACR25 LB22 @RheumNow https://t.co/HVEt8wFYmI

Effectiveness of b/tsDMARDs RA pts kidney dysfunction CorEvitas RA registry 9,569 pts Pts low eGFR = older more comorbidities less NSAIDs Reduced eGFR = 30% less likely to achieve remission Persists indeed of GC intake Is it a PK/PD related issue or somehow the reflection of https://t.co/KZuvPVa6eg

Microbiome signature for prediction of response to MTX in RA: Yay or Nay? Microbiome analysis 60pts, 23 MTX NR BL enrichment in specific species in MTX NR Looking at the graphs though, seems to be driven by a few pts Prediction model doesn't seem to perform greatly Sens 88% https://t.co/1yrSXdE6DG

Regulate-RA study, first-in-human Phase 1 study data show citrullinated protein (CitP)-targeted CAR-Tregs (SBT777101) are safe and show early efficacy in refractory RA. 67% had ≥50% joint count reduction by Week 4. A novel, non-cytotoxic approach to immune modulation for https://t.co/g153w3XVEK

The next VEXAS, but also maybe we can treat it? IDH1/2 Another clonal hematopoesis known to cause heme malignancy, but also some inflamm sequelae (autoinflamm-like e.g. PMR/GCA) & you can directly inhibit it Wow. We will hear more #ACR25 LB21 @RheumNow https://t.co/WL2ai5zb8Q https://t.co/Yi31xkhLO9

Ph2B RCT of Rosnilimab Tcell depleter (PD-1high Tph/Tfh, Teff) Wk 12 Primary Endpoint met Mean change DAS28-CRP at Wk 12 SC rosnilimab 100mg Q4W -2.06 400mg Q4W -2.12 600mg Q2W -2.06 PBO -1.69 >90% peripheral and synovial depletion pathogenic T cells 28 Wk Safety profile: https://t.co/XyVhJamFdp

#ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at WK16. Here, data showed sustained response through WK 52 across core domains inc. those who switched PBO->DEU. No major safety assoc. with JAK-i.A few acne @RheumNow https://t.co/tmzQMOtjev